Claude

Web Research

The Bottom Line from the Web

Centene is in the middle of its worst operational crisis in over a decade: a $1.8 billion Marketplace risk adjustment revenue shortfall forced the company to withdraw 2025 guidance in July 2025, triggering a 39% stock collapse and a securities fraud class action lawsuit (Lunstrum v. Centene). The 2025 GAAP loss of $6.7 billion – driven by $6.7 billion in goodwill and Magellan Health impairment charges – masks what management frames as a turnaround story into 2026, with adjusted EPS guidance of greater than $3.00 (vs. $2.08 in 2025). The most critical question the web reveals that filings alone cannot answer: whether the mid-30% Marketplace rate increases for 2026 are sufficient to offset structural morbidity elevation, or whether Centene is simply chasing a moving target while simultaneously facing OBBBA-driven Medicaid enrollment losses starting in 2027.

What Matters Most

Stock Price ($)

$37.28

Market Cap ($B)

18.3

Avg Target ($)

$43.18

Price/Book

0.87

1. July 2025 Guidance Withdrawal and $1.8B Risk Adjustment Shortfall

On July 1, 2025, Centene withdrew its full-year 2025 GAAP and adjusted EPS guidance after receiving Marketplace data from Wakely covering 22 of its 29 states (representing 72% of Marketplace membership). The data revealed market morbidity was "considerably higher than, and materially inconsistent with" Centene's assumptions, resulting in a preliminary $1.8 billion reduction in net risk adjustment revenue – a $2.75 per share adjusted EPS hit. Shares collapsed over 39% to levels not seen since 2017.

The guidance withdrawal was not just a one-time miss. It exposed that Centene's enrollment growth had attracted a sicker-than-expected population, calling into question the accuracy of its baseline morbidity models across the entire Marketplace book.

2. Securities Fraud Class Action (Lunstrum v. Centene)

A class action lawsuit was filed in the Southern District of New York (Case No. 25-cv-05659) on behalf of investors who purchased Centene securities between December 12, 2024, and June 30, 2025. The complaint alleges violations of the Securities Exchange Act, claiming management made materially misleading statements about Marketplace guidance before the July withdrawal. Multiple law firms (Robbins Geller, Glancy Prongay & Murray) are actively soliciting lead plaintiffs.

The class action creates ongoing legal overhang. With Centene having already paid over $1 billion in settlements related to its Envolve pharmacy benefit manager Medicaid overcharging allegations across 20+ states, this lawsuit adds a second layer of litigation risk.

3. 2025 Full-Year Results: $6.7B GAAP Loss, But Adjusted EPS of $2.08

Centene posted a GAAP diluted loss of $(13.53) per share for 2025, driven primarily by non-cash goodwill impairment charges. The consolidated health benefits ratio (HBR) reached 91.9% for the full year (up from 88.3% in 2024), with Q4 HBR at 94.3%. Adjusted diluted EPS was $2.08. Revenue grew nearly 20% to $194.8 billion, and operating cash flow was $5.1 billion. The company served 27.6 million members as of year-end 2025, with 20 million medical members.

Despite the GAAP loss, Centene generated $5.1 billion in operating cash flow and $5.05 billion in levered free cash flow during 2025, demonstrating that the cash generation engine remains intact even during a crisis year.

4. 2026 Guidance: Adjusted EPS Greater Than $3.00

Management issued 2026 adjusted diluted EPS guidance of greater than $3.00, implying over 40% year-over-year growth. This is anchored on: (a) mid-30% average Marketplace rate increases repriced across 95%+ of membership, (b) continued Medicaid HBR improvement (Q4 2025 Medicaid HBR of 93.0% showed 40 bps sequential improvement), and (c) Medicare Advantage progress toward breakeven by 2027. Notably, the 2026 guidance assumes zero share repurchases.

5. OBBBA and Enhanced APTC Expiration: Structural Headwinds

The One Big Beautiful Bill Act (OBBBA) signed in 2025 has multiple negative implications for Centene. The expiration of enhanced Advance Premium Tax Credits (APTCs) for Marketplace plans is driving an expected enrollment decline – Centene guided to approximately 3.5 million Marketplace members at Q1 2026 end, down from significantly higher levels. Marketplace revenue is expected to decrease by approximately $8 billion in 2026. OBBBA also introduces Medicaid work requirements (80 hours/month of community engagement) effective 2027, with RAND estimating $664 billion in cumulative state Medicaid budget reductions.

The OBBBA represents a long-term structural threat to Centene's Medicaid business (64% of membership). Work requirements historically cause significant disenrollment, and Centene's core customer base of low-income populations is most vulnerable to these changes.

6. Magellan Health Divestiture at a Loss

In December 2025, Centene signed a definitive agreement to divest its remaining Magellan Health businesses to Madison Health Group. The Company recorded $513 million ($389 million after-tax) in non-cash impairment charges related to the pending divestiture. Centene had previously completed the divestiture of Magellan Specialty Health for approximately $660 million ($400 million cash + $260 million in notes). The Magellan acquisition, completed in January 2022 for $2.2 billion, has been a value-destroying deal.

7. Medicare Advantage: CMS Rate Surprise and Star Ratings Recovery

In early April 2026, CMS finalized higher-than-expected Medicare Advantage payment rates, sending health insurer stocks higher. Centene's average Star rating improved to 3.39 (from 3.14 in 2025), with approximately 46% of members now in plans rated 3.5 stars or better – a 23% improvement. The company targets Medicare Advantage breakeven by 2027, supported by Star ratings recovery, risk-corridor containment in Part D, and network optimization.

The CMS Medicare Advantage rate increase is a near-term positive catalyst. Barclays reaffirmed its Buy rating on CNC following the announcement, and BofA raised its target to $34 from $32.

8. Medicaid Cost Pressures: Behavioral Health, Home Health, and Specialty Drugs

Centene identified three primary Medicaid cost drivers throughout 2025: behavioral health (accounting for roughly half of excess costs, with applied behavioral analysis/ABA therapy for autism being a major contributor), home health, and high-cost specialty drugs. The company successfully advocated for improved revenue in its Florida Children's Medical Services program and is pursuing state-by-state rate adequacy improvements. Florida and New York have been particularly challenging states.

9. Analyst Sentiment: Consensus Has Collapsed

No Results

The average analyst target price has fallen from the mid-$80s (early 2025) to around $43.18 currently (Yahoo Finance 1Y target). Fintel reports an average target of $47.42. The consensus rating is mixed: approximately 5 Buy, 13 Hold, and some Sell/Underperform ratings. The stock trades at ~12x forward P/E, well below historical averages for managed care companies.

10. Notable Insider Buying During the Crisis

CEO Sarah London purchased 19,230 shares on August 8, 2025, at approximately $25.50/share ($490,365 total), and a separate purchase of 4,117 shares ($250,313). CFO Andrew Asher purchased 17,200 shares on November 13, 2024. Director Thomas Greco purchased 17,000 shares for approximately $1.02 million. In the most recent 3 months, insiders have bought approximately $739,000 worth of shares with no open-market sales.

The insider buying pattern -- particularly CEO London's purchase near the 52-week low of $25.08 (August 7, 2025) -- signals management confidence in the turnaround. No insiders have been conducting open-market sales.

Recent News Timeline

No Results

Page / 2 10 of 16 records

What the Specialists Asked

Insider Spotlight

No Results

Key Observations:

The insider buying pattern is notable and bullish. CEO London's August 2025 purchase near the $25.08 all-time low demonstrates personal conviction. CFO Asher and Director Greco also made six-figure open-market purchases. Over the last 3 months, insiders have purchased approximately $739,000 worth of shares with zero open-market sales. All recent Form 4 filings show only compensation-related grants and tax-withholding dispositions – no voluntary selling.

David Einhorn's Greenlight Capital was noted as holding CNC in its portfolio as of February 2026, described as part of an "eclectic stock portfolio" that "shuns AI" in favor of value plays (CNBC, February 18, 2026).

Institutional Ownership Shifts (Q1 2025 13F filings):

FMR (Fidelity) added 5.2 million shares (+24.3%), and AQR Capital added 3.3 million shares (+42.7%). On the sell side, Wellington Management reduced by 5.5 million shares (-36.0%), Harris Associates sold 4.3 million shares (-16.8%), and Millennium Management reduced by 3.7 million shares (-60.4%).

Industry Context

Managed Care Sector Under Dual Pressure

The managed care sector faces simultaneous headwinds from OBBBA legislation and elevated medical cost trends. The OBBBA's Medicaid provisions – including work requirements effective January 2027, six-month redetermination cycles, and restrictions on state provider taxes – will reduce federal Medicaid spending by an estimated $900 billion+ over 10 years. An estimated 4.8 million people may lose Marketplace coverage in 2026 if enhanced premium tax credits are not restored.

Medicare Advantage: Rate Tailwind

The April 2026 CMS final rate notice provided a positive surprise for the managed care sector, with higher-than-expected Medicare Advantage payment rates. This benefits all major MCOs, but is particularly important for Centene as it works toward Medicare Advantage breakeven by 2027. UnitedHealth, Humana, and Elevance Health all rallied on the news.

Competitive Landscape

Centene's primary competitors in Medicaid managed care include Molina Healthcare (MOH), Elevance Health (ELV), and UnitedHealth Group (UNH). In the Marketplace/ACA exchange business, competitors include Oscar Health (OSCR), Molina, and Elevance. Centene differentiates through its focus on underserved populations and community-based healthcare services, which creates a "competitive moat" in member retention. However, the company lags peers in Medicare membership and profitability metrics – ROE is -28.7% (TTM) and net margin is -3.79%.

Georgia and Texas Medicaid Contract Risks

Centene faces ongoing Medicaid contract risks in key states. In Georgia, the company was involved in formal protests over a multibillion-dollar Medicaid contract. In Texas, Centene also planned to file a protest over state Medicaid scoring decisions. These competitive dynamics are standard in the industry but represent meaningful revenue concentration risk for Centene, which derives the majority of its revenue from government contracts.